Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Equity Income (2022 - 2024)

Amphastar Pharmaceuticals has reported Equity Income over the past 3 years, most recently at -$573000.0 for Q1 2024.

  • Quarterly results put Equity Income at -$573000.0 for Q1 2024, up 27.01% from a year ago — trailing twelve months through Dec 2024 was -$573000.0 (up 71.08% YoY), and the annual figure for FY2024 was -$573000.0, up 71.08%.
  • Equity Income for Q1 2024 was -$573000.0 at Amphastar Pharmaceuticals, down from -$505000.0 in the prior quarter.
  • Over the last five years, Equity Income for AMPH hit a ceiling of -$57000.0 in Q4 2022 and a floor of -$785000.0 in Q1 2023.
  • Median Equity Income over the past 3 years was -$390000.0 (2023), compared with a mean of -$414555.6.
  • Biggest five-year swings in Equity Income: crashed 785.96% in 2023 and later increased 27.01% in 2024.
  • Amphastar Pharmaceuticals' Equity Income stood at -$57000.0 in 2022, then crashed by 785.96% to -$505000.0 in 2023, then fell by 13.47% to -$573000.0 in 2024.
  • The last three reported values for Equity Income were -$573000.0 (Q1 2024), -$505000.0 (Q4 2023), and -$390000.0 (Q3 2023) per Business Quant data.